Sustainable access to high-quality insulin is becoming a reality for people living with diabetes in several low- to middle-income countries (LMICs) in Africa. Through our collaboration with EVA pharma, we’re aiming to expand access to affordable insulin to at least one million people living with diabetes in LMICs annually by 2030. The local regulatory approval of EVA Pharma’s insulin drug product in Egypt—using Lilly's insulin active pharmaceutical ingredient and pro bono technical assistance—is an important milestone towards our goal. Learn more about our collaboration and progress: https://e.lilly/4iCXFaR.
Eli Lilly and Company
Pharmaceutical Manufacturing
Indianapolis, Indiana 1,939,966 followers
About us
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
- Website
-
http://www.lilly.com/
External link for Eli Lilly and Company
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Indianapolis, Indiana
- Type
- Public Company
- Specialties
- Pharmaceutical Development, Pharmaceuticals, Biotech, and Biopharmaceuticals
Locations
-
Primary
Get directions
Lilly Corporate Center
Indianapolis, Indiana 46285, US
Employees at Eli Lilly and Company
Updates
-
When U.S. Paralympian Nick Mayhugh noticed his grandfather’s memory slipping, he knew it was important to speak up, even as a kid. Nick recently sat down with Anne White, the leader of our Neuroscience team, to talk about why it’s so important to recognize the early signs of Alzheimer’s disease—and seek advice from professionals. #WeAreLilly
-
This Thursday, tune in to Lilly Oncology's event featuring an insightful conversation between Lilly’s John Pagel and the Lymphoma Research Foundation's Meghan Gutierrez. Together, they’ll discuss how partnerships in research and advocacy are essential to advancing #BloodCancer care, closing treatment gaps and improving patient outcomes. https://e.lilly/4fZuugi
-
-
Wishing you a safe and happy holiday season from all of us at Lilly. #WeAreLilly
-
You can be passionate about your hobby. You can be passionate about your work. Can you be passionate about how your hobby drives your work? For Lilly Scientist Jay Bolden, the answer is yes! Jay’s birding hobby and his work testing medicine safety intertwined in a big way when he realized one of the standard industry tests he used in his lab came from purified horseshoe crab blood. The demand for their blood had a negative impact not only on the horseshoe crabs, but also on the other animals that depend on them. Learn more about how Jay’s hobby fueled a push for us to lead the industry in adopting a synthetic alternative that could help rebalance a delicate ecosystem: https://e.lilly/3ZGfzRx #WeAreLilly
-
People living with advanced or metastatic breast cancer (MBC) currently have limited treatment options. Today at #SABCS24, we presented new Phase 3 data that may have a potential impact. Learn more: https://e.lilly/4gxxd0x
-
Clinical trials are important studies to verify the safety and efficacy of medicines. While the data provided by these studies tell an important story about the medicines, it’s the people participating in the studies—people like Paul—whose stories should be shared. See more of Paul’s story here: https://e.lilly/49wU8qq #WeAreLilly
-
Today at #ASH24, we presented results from the first of our five Phase 3 randomized trials for people living with certain blood cancers. These data offer new scientific evidence in people living with pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Learn more: https://e.lilly/41xQxGq
-
We welcome the ADA’s guidance against unapproved compounded medicines, which rightly points out the “uncertainty about their content, safety, quality, and effectiveness.” No patient should be exposed to unapproved knockoff drugs with heightened risks, particularly when safe and effective FDA-approved medicines are available. Mass-produced unapproved drugs may expose patients to potentially life-threatening risks. Patient safety remains Lilly's top concern, but our efforts alone are not enough. We appreciate the ADA’s continued commitment to patient safety.
Today, the American Diabetes Association® issued a statement against using non-FDA approved compounded GLP-1 and dual GIP/GLP-1 RA products. Safety, quality, and effectiveness may be at risk. Read more at bit.ly/4eVY6tN.
-
-
Our work is never done when it comes to manufacturing current and future medicines to help people achieve their best health. Today’s announcement—a $3 billion expansion to our recently acquired manufacturing facility in Kenosha County, Wisconsin—is the single largest U.S. manufacturing investment outside our home state of Indiana, and will help meet the growing demand for our diabetes, obesity and future medicines across therapeutic areas. https://e.lilly/4fYeVp7 #WeAreLilly